Roivant Sciences LTD 8-K filings

Roivant Sciences announced first-quarter 2026 financial results, highlighting strong progress in its drug development pipeline, including upcoming data readouts and a potential September 2026 launch for brepocitinib.

Roivant Sciences announced fourth quarter and fiscal year 2026 financial results, highlighting significant clinical trial progress and a major litigation settlement.

Roivant Sciences' subsidiary Genevant and Arbutus Biopharma reached a settlement with Moderna, resolving global patent litigation over mRNA vaccine technology for an initial $950 million and a potential $1.3 billion contingent payment.

Roivant Sciences' subsidiary, Genevant Sciences, and Arbutus Biopharma have reached a global settlement with Moderna for up to $2.25 billion over LNP technology patent infringement, alongside an increased $1 billion share repurchase program.

The U.S. Food and Drug Administration has accepted Priovant Therapeutics' New Drug Application for brepocitinib for dermatomyositis and granted it Priority Review, with a PDUFA target action date in Q3 2026.

Roivant Sciences announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, alongside its Q3 2025 financial results and a significant Immunovant financing.

Roivant Sciences Ltd. announced accelerated timelines for several key pipeline programs and a strong financial position at its 2025 Investor Day, signaling a new phase of growth and potential commercial launches.

Roivant Sciences reports strong Phase 3 brepocitinib data in dermatomyositis, significant cash reserves, and progress across its pipeline, despite a delay in batoclimab TED study readouts.

Roivant Sciences Ltd. announced positive Phase 3 VALOR study results for brepocitinib in dermatomyositis, demonstrating significant clinical improvement and a consistent safety profile.

Roivant Sciences Ltd. shareholders approved all proposals at its 2025 Annual General Meeting, including director re-elections and auditor ratification.

Immunovant's batoclimab shows durable, treatment-free remission in uncontrolled Graves' disease patients, with registrational trials for IMVT-1402 underway.

Roivant Sciences reports increased Q1 losses driven by higher R&D and G&A expenses, while advancing multiple clinical programs and completing a significant share repurchase.

Roivant Sciences Ltd. has announced a new common share repurchase program of up to $500 million, following the full exhaustion of its previous $1.5 billion program.

Roivant Sciences Ltd. announced its financial results for the fourth quarter and fiscal year ended March 31, 2025, reporting increased losses from continuing operations despite significant clinical advancements and a substantial share repurchase program.

Immunovant announces a strategic realignment with Roivant, including leadership changes and the expansion of IMVT-1402 into new indications like Sjgrens Disease and Cutaneous Lupus Erythematosus.

Roivant Sciences Ltd. has entered into a consulting agreement with its former Chief Accounting Officer, Rakhi Kumar, to provide advisory and transition services.

Roivant reports positive topline results from its Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial results from its Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), demonstrating significant clinical improvements.

Roivant Sciences Ltd. announces the departure of Rakhi Kumar as Principal Accounting Officer and the appointment of Jennifer Humes, formerly of JPMorgan Chase, to the role, effective February 20, 2025.

Roivant Sciences Ltd. announced its financial results for the third quarter ended December 31, 2024, and provided a business update, highlighting progress in clinical trials and pipeline expansion.

Roivant Sciences' Kinevant subsidiary announced that its Phase 2 RESOLVE-Lung study of namilumab in chronic active pulmonary sarcoidosis failed to show treatment benefit, leading to the discontinuation of further development for this indication.

Roivant Sciences announced its financial results for the second quarter ended September 30, 2024, along with key clinical and business updates, including progress in multiple therapeutic programs and significant share repurchases.

Organon has successfully completed its acquisition of Dermavant, gaining access to the innovative topical treatment VTAMA cream for plaque psoriasis and a potential treatment for atopic dermatitis.

Organon has agreed to acquire Dermavant for up to $1.2 billion in cash, including milestone payments and royalties, marking a significant move in the dermatology space.

Organon will acquire Dermavant, a Roivant subsidiary, for up to $1.2 billion, gaining access to the innovative dermatology treatment VTAMA and expanding its global reach.

Roivant Sciences Ltd. successfully held its 2024 Annual General Meeting, with shareholders approving all proposals, including the re-election of directors and ratification of the auditor.

Roivant announces a new pipeline program, mosliciguat, a potential first-in-class inhaled treatment for pulmonary hypertension associated with interstitial lung disease, showing significant reductions in pulmonary vascular resistance in early trials.

Immunovant reports strong results from a Phase 2a trial of batoclimab in Graves' Disease, showing high response rates and a correlation between IgG reduction and clinical outcomes, with a pivotal trial of IMVT-1402 expected by year-end.

Roivant Sciences announced its first quarter 2024 financial results, highlighted by a net income of $57.5 million and progress in key clinical trials.

Dermavant, a subsidiary of Roivant Sciences, has renegotiated its debt obligations, reducing potential cash payments by over $300 million, with approximately $225 million expected over the next three fiscal years.

Roivant Sciences announced its financial results for the fourth quarter and fiscal year ended March 31, 2024, highlighting positive clinical trial data, a significant share repurchase, and a substantial gain from the sale of Telavant.